Norma Therese Walks, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1521 E Tangerine Rd Ste 201, Oro Valley, AZ 85755 Phone: 520-605-5664 Fax: 520-605-5665 |
Dr. Mark Thomas Cenac, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 11765 N Robi Pl, Oro Valley, AZ 85737 Phone: 520-292-2286 Fax: 520-575-5992 |
Margaret Riesenberg-karges, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1850 E Innovation Park Dr, Oro Valley, AZ 85755 Phone: 520-797-3000 |
News Archive
Despite recent advances in therapy, melanoma remains the deadliest, most aggressive form of skin cancer as incidence rates continue to climb. Now, a team of melanoma scientists from The Wistar Institute and the University of Pennsylvania received a $12.5 M, five-year program project grant (P01) from the National Institutes of Health to continue trailblazing research on targeted therapies in melanoma.
Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc. announced today that the U.S. Food and Drug Administration has accepted for review the complete response submission made by Endo to the new drug application for its long-acting testosterone undecanoate injection, AVEED, intended for men diagnosed with hypogonadism.
Curtailing the imminent rise in Alzheimer's disease (AD) will require early, accurate diagnostic tests and treatments, and researchers are closer to achieving these two goals. New findings in medical imaging, molecular analysis of neurological diseases, and development of treatments using mouse models were presented at Neuroscience 2012, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news about brain science and health.
The U.S. Food and Drug Administration today approved Firazyr (icatibant) Injection for the treatment of acute attacks of a rare condition called hereditary angioedema (HAE) in people ages 18 years and older.
› Verified 7 days ago